🔖 What This Document Is

This is an 8-K filing with an attached Exchange Agreement (Exhibit 10.1). An 8-K is a "current report" companies use to announce major events to shareholders.

👉 In simple terms: Lunai Bioworks is announcing a deal to swap company debt for ownership shares. An investor who lent the company money (a "Holder") is agreeing to cancel that loan in exchange for a large batch of new stock and warrants. This filing reveals the template agreement they plan to use.

🧬 What Lunai Bioworks Does

Lunai Bioworks (NASDAQ: LNAI) is an AI-powered life sciences company. They're not making drugs themselves in the traditional way.

👉 Think of them as a high-tech "discovery engine." They use artificial intelligence (AI) and machine learning to analyze huge sets of clinical and biological data. Their goal is to find new drug targets and develop "precision therapeutics" faster and more successfully, especially for tough diseases in the brain (central nervous system) and cancer (oncology).

🤝 The Deal: Debt-for-Equity Exchange

This is the core of the filing. A specific investor (the "Holder") is owed money under an "Investor Note."

Here's what the swap entails:

• What the Holder gives up: The right to be repaid the total outstanding debt (principal + interest). The exact dollar amount is blank in this template ($__________).
• What the Holder gets:
  1. Common Stock: A specific number of new shares (_______ shares) of Lunai Bioworks.
  2. Warrants: A separate number of warrants (_______ warrants). Warrants are like long-term options to buy more shares at a set price.
• Result: The original debt note is cancelled. The Holder becomes a shareholder.

Why do this? For the company, it eliminates debt from its balance sheet without spending cash. For the investor, it transforms a loan (which only gets repaid principal + interest) into an ownership stake (which has potentially unlimited upside if the stock price rises).

⚙️ How The Deal Gets Done

This isn't automatic. The agreement lists key conditions that must be met for the swap to happen ("Closing"):

• Nasdaq Approval: Lunai must file a form with Nasdaq (where its stock trades) and get no objections, or clear any objections, for issuing all these new shares.
• Board Approval: The company's board of directors must approve the deal.
• Paperwork: Both parties sign the agreement, and Lunai must file this 8-K with the SEC promptly.

Once closed, the company's transfer agent will issue the shares and warrants to the Holder, and the debt is gone.

💰 Why This Matters Financially

This deal has two major financial impacts:

• 👍 Deleveraging (A Positive): Lunai's total debt decreases. This strengthens the balance sheet by reducing liabilities, which can make the company look healthier to other lenders or investors.
• ⚠️ Shareholder Dilution (A Risk): The company is creating a large number of new shares from scratch and giving them to the Holder. This means each existing share now represents a smaller piece of the overall company. This can put downward pressure on the stock price.

🔮 What This Signals & What's Next

• A Signal of Confidence? The Holder is essentially betting that Lunai's stock will be worth more in the future than the debt they're owed. They're trading guaranteed repayment for potential equity upside.
• Focus on Liquidity: By converting debt to equity, Lunai preserves its precious cash for operations and R&D, not debt servicing. This is common for early-stage biotech firms burning cash.
• Next Steps: The company will now work to get the required Nasdaq and board approvals to finalize this and future similar exchanges.

⚖️ Big Picture: Strengths & Risks

• 👍 Strengths of this Move:
  • Reduces financial pressure and debt obligations.
  • Attracts a long-term investor whose success is now tied to the stock's performance.
  • Avoids using cash to pay back the loan.
• ⚠️ Risks to Watch:
  • Dilution: This deal (and potentially others like it) will increase the total share count, reducing earnings per share and your ownership percentage if you're an existing shareholder.
  • Execution Risk: The company's AI platform needs to deliver on its promise to discover viable drugs. The value of these new shares depends entirely on future success.
  • Regulatory Hurdle: The deal is contingent on Nasdaq's approval, which is not guaranteed.

🧠 The Analogy

Imagine you own a small, promising coffee shop that's a bit short on cash. You owe your friend $10,000. Instead of paying them back that $10,000 in cash (which would hurt your shop), you offer them a deal: "Forget the $10,000 debt. Instead, I'll give you a 10% ownership stake in my coffee shop." Your friend agrees because they believe the shop will be worth a lot more one day. You get to keep your cash to grow the business, and your friend becomes your business partner. This is exactly what Lunai is doing with its "coffee shop" (the company) and its investor.

📇 Key Contacts & People

• Media Relations Contact: Lunai Bioworks, Inc.
• Email: [email protected]

🧩 Final Takeaway

Lunai Bioworks is strategically converting debt into equity to clean up its balance sheet and conserve cash for its AI drug discovery mission. While this relieves financial pressure, it comes at the cost of diluting existing shareholders. The success of this move hinges on the company's future scientific and commercial achievements.